Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
CVKD
#4817
Cadrenal Therapeutics, Inc. Common Stock
4.7
9
USD
-4.01%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
-4.01%
Changement Mensuel
-35.53%
Evolution sur 6 mois
-13.22%
Changement Annuel
-13.22%
Clôture Précédente
4.9
9
Open
4.7
9
Bid
Ask
Low
4.7
9
High
4.7
9
Volume
2
Marchés
Actions des Marchés US
Soins de Santé
CVKD
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
775.64 K
5 M
1.88 M
2.51 M
—
Valuation ratios
Enterprise value
—
2.22 M
17.24 M
12.99 M
84.84 M
Price to earnings ratio
—
-1.07
-1.66
-1.02
-6
Price to sales ratio
—
-12.1
—
—
—
Price to cash flow ratio
—
-2.54
-2.4
-1.07
-7.12
Price to book ratio
—
1.16
2.38
4.94
7.91
Enterprise value to EBITDA ratio
—
-0.18
-1.57
—
—
Profitability ratios
Return on assets %
-0.01
-0.98
-1.05
-3.06
-2.46
Return on equity %
0
-1.09
-1.43
-4.83
-3.57
Return on invested capital %
—
-37 K
-148.21 K
-595.73 K
—
Gross margin %
—
129.74
—
—
—
Operating margin %
—
1 031.27
—
—
—
EBITDA margin %
—
1 157.07
—
—
—
Net margin %
—
1 129.12
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
0.55
10.27
3.77
2.72
13.61
Inventory turnover
—
—
—
—
—
Asset turnover
—
-0.16
0
—
—
Solvency ratios
Debt to assets ratio
1.48
0
—
—
—
Debt to equity ratio
-0.21
0
—
—
—
Long term debt to total assets ratio
-0.14
-0.09
—
—
—
Long term debt to total equity ratio
0.02
-0.1
—
—
—
Per share metrics
Operating cash flow per share
—
-3.92
-6.03
-6.32
-6.51
EBIT per share
—
-9.55
-8.99
—
—
EBITDA per share
—
-9.52
-8.99
—
—
Total debt per share
—
0
—
—
—
Cash per share
—
9.34
8.2
2.01
10.72
Net current asset value per share
—
9.44
8.29
2.17
11.52
Tangible book value per share
—
8.55
6.1
1.37
8.22
Working capital per share
—
8.52
6.09
1.37
8.2
Book value per share
—
8.55
6.1
1.37
8.22
Nouvelles
Cadrenal annonce une perte au T4 et finalise une réunion avec la FDA
Cadrenal schedules FDA meeting for HIT drug CAD-1005
L’action Cadrenal Therapeutics bondit après les résultats d’essai de Phase 2
Cadrenal Therapeutics stock surges on Phase 2 trial results
Le CAD-1005 de Cadrenal réduit les caillots sanguins dans l’essai HIT
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial
Cadrenal met en avant le potentiel de l’inhibiteur 12-LOX pour traiter un trouble sanguin
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc.